EHA Library - The official digital education library of European Hematology Association (EHA)

BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY
Author(s): ,
Irene Urbino
Affiliations:
Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italie;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italien;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italia;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italy;Hematology Department,AOU Città della Salute e della Scienza
,
Etienne Lengline
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Marco Cerrano
Affiliations:
Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italie;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italien;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italia;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italy;Hematology Department,AOU Città della Salute e della Scienza
,
Florence Rabian
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Rathana Kim
Affiliations:
Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Marie Sebert
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Raphael Itzykson
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Ernesta Audisio
Affiliations:
Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italie;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italien;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italia;Hematology Department,AOU Città della Salute e della Scienza di Torino,Torino,Italy;Hematology Department,AOU Città della Salute e della Scienza
,
Lionel Ades
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Hervé Dombret
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Emmanuel Raffoux
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
,
Dario Ferrero
Affiliations:
Department of Molecular Biotechnology and Health Sciences,Division of Hematology, University of Torino,Torino,Italie;Department of Molecular Biotechnology and Health Sciences,Division of Hematology, University of Torino,Torino,Italien;Department of Molecular Biotechnology and Health Sciences,Division of Hematology, University of Torino,Torino,Italia;Department of Molecular Biotechnology and Health
,
Emmanuelle Clappier
Affiliations:
Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Laboratory,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
Nicolas Boissel
Affiliations:
Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Frankreich;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,France;Hematology Department,Saint-Louis Hospital - Université de Paris,Paris,Francia;Hema
(Abstract release date: 05/12/22) EHA Library. Urbino I. 06/10/22; 357237; P374
Irene Urbino
Irene Urbino
Contributions
Abstract
Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P374

Type: Poster presentation

Session title: Acute lymphoblastic leukemia - Clinical

Background
Blinatumomab is a CD3/CD19 bispecific T-cell engager approved for the treatment of relapsed/refractory (R/R) or minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (B-ALL). Recent phase 3 studies in children and young adults with B-ALL in first relapse suggested that blinatumomab used as consolidation after chemotherapy salvage could be more beneficial than given as single agent in overt relapse. Whereas current strategies aim to demonstrate the benefit of blinatumomab in first line, the optimal use of blinatumomab in adult patients with first B-ALL relapse still deserves to be further explored

Aims
To evaluate the efficacy of blinatumomab given as consolidation in adults with B-ALL in a real-world setting

Methods
We retrospectively included 115 consecutive patients with B-ALL treated with blinatumomab from April 2012 until June 2021 at Saint-Louis Hospital, Paris, France (n=100), and at AOU Città della Salute e della Scienza, Turin, Italy (n=15). Patients included in clinical trials were excluded. Patients were divided in three subgroups: 68 patients treated in 1st complete remission (CR1), 31 patients treated in 2nd CR after chemotherapy-base salvage therapy (CR2), and 16 patients treated in overt relapse (R/R). Patients in CR1 received blinatumomab for MRD persistence (n=59/68, 87%) or due to inability to receive standard consolidation (n=9/68, 13%, off-label use). The number of blinatumomab cycles along with the use of chemotherapy and/or of allogeneic hematopoietic stem cell transplant (alloHSCT) after blinatumomab was up to physician choice.

Results
The median age of patients was 37 years (range, 15-84). Among the 115 patients, 24% (n=28) were Philadelphia (Ph)-positive. Age, sex, baseline disease features and genetic risk categories did not differ between subgroups. After blinatumomab a complete MRD-response was achieved in 83% of CR1 and 86% of CR2 patients (p=.99). A complete remission was reached by 9/15 R/R patients (60%). In the 3 subgroups, the median number of blinatumomab cycles given was 2 (range, 1-6). Forty-six patients (42%) treated in CR (41% CR1, 45% CR2) and 4 R/R patients (25%) were bridged to allo-HSCT in continuous CR after blinatumomab. With a median follow up of 3.1 years, 3-year DFS was 68% in CR1 and 67% in CR2 patients (p=0.41); 3-year OS was 80% in CR1 and 71% in CR2 patients (p=0.32). In R/R patients, 3-year DFS and OS were 13% and 20% respectively. Considering patients who received blinatumomab in CR (CR1+CR2), univariate analysis showed that higher MRD levels both before and after blinatumomab were associated with shorter DFS, while only MRD response to blinatumomab was associated with OS. Both pre- and post-blinatumomab MRD levels retained significance in bivariate analysis for DFS

Conclusion
The present study underlines the efficacy of blinatumomab in consolidation after chemotherapy-based salvage, showing comparable outcomes between patients treated in CR2 and CR1. In CR2 patients, promising DFS and OS were observed as compared to historical cohorts of patients treated with chemotherapy alone or with blinatumomab in overt relapse. Our data suggest that blinatumomab should be preferably used in consolidation rather than as salvage therapy in patients with B-ALL in first relapse

Keyword(s): Acute lymphoblastic leukemia, Bispecific, Consolidation, Relapse

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until Monday, August 15, 2022 on the Congress platform.

Abstract: P374

Type: Poster presentation

Session title: Acute lymphoblastic leukemia - Clinical

Background
Blinatumomab is a CD3/CD19 bispecific T-cell engager approved for the treatment of relapsed/refractory (R/R) or minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (B-ALL). Recent phase 3 studies in children and young adults with B-ALL in first relapse suggested that blinatumomab used as consolidation after chemotherapy salvage could be more beneficial than given as single agent in overt relapse. Whereas current strategies aim to demonstrate the benefit of blinatumomab in first line, the optimal use of blinatumomab in adult patients with first B-ALL relapse still deserves to be further explored

Aims
To evaluate the efficacy of blinatumomab given as consolidation in adults with B-ALL in a real-world setting

Methods
We retrospectively included 115 consecutive patients with B-ALL treated with blinatumomab from April 2012 until June 2021 at Saint-Louis Hospital, Paris, France (n=100), and at AOU Città della Salute e della Scienza, Turin, Italy (n=15). Patients included in clinical trials were excluded. Patients were divided in three subgroups: 68 patients treated in 1st complete remission (CR1), 31 patients treated in 2nd CR after chemotherapy-base salvage therapy (CR2), and 16 patients treated in overt relapse (R/R). Patients in CR1 received blinatumomab for MRD persistence (n=59/68, 87%) or due to inability to receive standard consolidation (n=9/68, 13%, off-label use). The number of blinatumomab cycles along with the use of chemotherapy and/or of allogeneic hematopoietic stem cell transplant (alloHSCT) after blinatumomab was up to physician choice.

Results
The median age of patients was 37 years (range, 15-84). Among the 115 patients, 24% (n=28) were Philadelphia (Ph)-positive. Age, sex, baseline disease features and genetic risk categories did not differ between subgroups. After blinatumomab a complete MRD-response was achieved in 83% of CR1 and 86% of CR2 patients (p=.99). A complete remission was reached by 9/15 R/R patients (60%). In the 3 subgroups, the median number of blinatumomab cycles given was 2 (range, 1-6). Forty-six patients (42%) treated in CR (41% CR1, 45% CR2) and 4 R/R patients (25%) were bridged to allo-HSCT in continuous CR after blinatumomab. With a median follow up of 3.1 years, 3-year DFS was 68% in CR1 and 67% in CR2 patients (p=0.41); 3-year OS was 80% in CR1 and 71% in CR2 patients (p=0.32). In R/R patients, 3-year DFS and OS were 13% and 20% respectively. Considering patients who received blinatumomab in CR (CR1+CR2), univariate analysis showed that higher MRD levels both before and after blinatumomab were associated with shorter DFS, while only MRD response to blinatumomab was associated with OS. Both pre- and post-blinatumomab MRD levels retained significance in bivariate analysis for DFS

Conclusion
The present study underlines the efficacy of blinatumomab in consolidation after chemotherapy-based salvage, showing comparable outcomes between patients treated in CR2 and CR1. In CR2 patients, promising DFS and OS were observed as compared to historical cohorts of patients treated with chemotherapy alone or with blinatumomab in overt relapse. Our data suggest that blinatumomab should be preferably used in consolidation rather than as salvage therapy in patients with B-ALL in first relapse

Keyword(s): Acute lymphoblastic leukemia, Bispecific, Consolidation, Relapse

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies